American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
MA Sekeres, G Guyatt, G Abel, S Alibhai… - Blood …, 2020 - ashpublications.org
Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …
Comparison between decitabine and azacitidine for patients with acute myeloid leukemia and higher-risk myelodysplastic syndrome: a systematic review and network …
J Ma, Z Ge - Frontiers in pharmacology, 2021 - frontiersin.org
Background: The hypomethylating agents (HMAs) azacitidine (AZA) and decitabine (DAC)
have been widely used in patients with acute myeloid leukemia (AML) and higher-risk …
have been widely used in patients with acute myeloid leukemia (AML) and higher-risk …
[HTML][HTML] Moving toward individualized target-based therapies in acute myeloid leukemia
A Bazinet, HM Kantarjian - Annals of Oncology, 2023 - Elsevier
Highlights•AML is a highly heterogeneous disease and warrants an individualized
approach.•The advent of effective low-intensity regimens has improved outcomes in older …
approach.•The advent of effective low-intensity regimens has improved outcomes in older …
A review of FDA-approved acute myeloid leukemia therapies beyond '7+ 3'
A Bazinet, S Assouline - Expert review of hematology, 2021 - Taylor & Francis
Introduction: The standard anthracycline and cytarabine-based chemotherapy for acute
myeloid leukemia (AML) has changed relatively little since the 1970s and produces …
myeloid leukemia (AML) has changed relatively little since the 1970s and produces …
Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized …
M Lübbert, S Suciu, A Hagemeijer, B Rüter… - Annals of …, 2016 - Springer
In a study of elderly AML patients treated with the hypomethylating agent decitabine (DAC),
we noted a surprisingly favorable outcome in the (usually very unfavorable) subgroup with …
we noted a surprisingly favorable outcome in the (usually very unfavorable) subgroup with …
Hypomethylating agents as a therapy for AML
C Gardin, H Dombret - Current hematologic malignancy reports, 2017 - Springer
Acute myeloid leukemia (AML) is predominantly a disease of older adults associated with
poor long-term outcomes with available therapies. Used as single agents, hypomethylating …
poor long-term outcomes with available therapies. Used as single agents, hypomethylating …
How and when to decide between epigenetic therapy and chemotherapy in patients with AML
H Dombret, R Itzykson - Hematology 2014, the American …, 2017 - ashpublications.org
Remission induction with chemotherapy has long been the frontline treatment of acute
myeloid leukemia (AML). However, intensive therapy is limited in frail patients by its …
myeloid leukemia (AML). However, intensive therapy is limited in frail patients by its …
Hypomethylating chemotherapeutic agents as therapy for myelodysplastic syndromes and prevention of acute myeloid leukemia
VG Sorrentino, S Thota, EA Gonzalez, P Rameshwar… - Pharmaceuticals, 2021 - mdpi.com
Myelodysplastic Syndromes (MDSs) affect the elderly and can progress to Acute Myeloid
Leukemia (AML). Epigenetic alterations including DNA methylation and chromatin …
Leukemia (AML). Epigenetic alterations including DNA methylation and chromatin …
Epigenetic therapy in hematological cancers
K Dimopoulos, K Grønbæk - Apmis, 2019 - Wiley Online Library
The increasing depth of knowledge about cancer biology throughout the last decades, has
underlined the importance of not only genetic aberrations, but also epigenetic abnormalities …
underlined the importance of not only genetic aberrations, but also epigenetic abnormalities …
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health …
L Pleyer, S Burgstaller, R Stauder… - Journal of Hematology & …, 2016 - Springer
Abstract Background The MDS-IWG and NCCN currently endorse both FAB and WHO
classifications of MDS and AML, thus allowing patients with 20–30% bone marrow blasts …
classifications of MDS and AML, thus allowing patients with 20–30% bone marrow blasts …